Cor Vasa 2024, 66(4):429-434 | DOI: 10.33678/cor.2024.038

(Atrial fibrillation in patients with hypertrophic cardiomyopathy)

Veronika Puchnerová, Michael Jenąovský, Petr Oą»ádal, Jiří Bonaventura
Kardiologická klinika, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Motol, Praha, Česká republika

Atrial fibrillation is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy. The review article focuses on the complex mechanisms of development of atrial fibrillation in this subgroup of patients and on specific aspects of treatment (anticoagulation therapy and rhythm control). The final part focuses on the arrhythmia's effect on clinical symptomatology and prognosis of patients with hypertrophic cardiomyopathy.

Keywords: Atrial fibrillation, Hypertrophic cardiomyopathy, Prognosis, Thromboembolic risk

Received: April 30, 2024; Revised: April 30, 2024; Accepted: May 1, 2024; Prepublished online: June 2, 2012; Published: September 9, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Puchnerová V, Jenąovský M, Oą»ádal P, Bonaventura J. (Atrial fibrillation in patients with hypertrophic cardiomyopathy). Cor Vasa. 2024;66(4):429-434. doi: 10.33678/cor.2024.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Maron BJ, Desai MY, Nishimura RA, et al. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;79;390-414. Go to original source... Go to PubMed...
    2. Ommen SR, Mital S. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation 2020;142:e558-e631. Go to original source... Go to PubMed...
    3. Rowin EJ, Hausvater A, Link MS, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2017;136:2420-2436. Go to original source... Go to PubMed...
    4. Olivotto I, Cecchi F, Casey SA, et al. Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy. Circulation 2001;104:2517-2524. Go to original source... Go to PubMed...
    5. Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: Prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 2014;3:001002. Go to original source... Go to PubMed...
    6. Guttmann OP, Pavlou M, O'Mahony C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart 2017;103:672-678. Go to original source... Go to PubMed...
    7. Debonnaire P, Joyce E, Hiemstra Y, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol 2017;10:e004052. Go to original source... Go to PubMed...
    8. Maron BJ, Haas TS, Maron MS, et al. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol 2014;113:1394-1400. Go to original source... Go to PubMed...
    9. Raphael CE, Liew AC, Mitchell F, et al. Predictors and Mechanisms of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2020;136:140-148. Go to original source... Go to PubMed...
    10. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232-2239. Go to original source... Go to PubMed...
    11. Liew AC, Vassiliou VS, Cooper R, Raphael CE. Hypertrophic cardiomyopathy - past, present and future. J Clin Med 2017;6:118. Go to original source... Go to PubMed...
    12. Hong JH, Schaff H V, Nishimura RA, et al. Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy Implications for Concomitant Valve Procedures. J Am Coll Cardiol 2016;68:1497-1504. Go to original source... Go to PubMed...
    13. Ashraf MA. Mitral Regurgitation in Hypertrophic Cardiomyopathy: A Narrative Review of Mechanism and Current Management. Int J Clin Cardiol 2022;9:248. Go to original source...
    14. Falasconi G, Pannone L, Slavich M, et al. Atrial fibrillation in hypertrophic cardiomyopathy: pathophysiology, diagnosis and management. Am J Cardiovasc Dis 2020;10:409-418.
    15. Olivotto I, Maron BJ, Cecchi F. Clinical Significance of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Curr Cardiol Rep 2001;3:141-146. Go to original source... Go to PubMed...
    16. Gruver EJ, Fatkin D, Dodds GA, et al. Familial Hypertrophic Cardiomyopathy and Atrial Fibrillation Caused by Arg663His Beta-Cardiac Myosin Heavy Chain Mutation. Am J Cardiol 1999;83(12A):13H-18H. Go to original source... Go to PubMed...
    17. Eiras S, Narolska NA, van Loon RB, et al. Alterations in contractile protein composition and function in human atrial dilatation and atrial fibrillation. J Mol Cell Cardiol 2006;41:467-477. Go to original source... Go to PubMed...
    18. Bongini C, Ferrantini C, Girolami F, et al. Impact of genotype on the occurrence of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2016;117:1151-1159. Go to original source... Go to PubMed...
    19. Bonaventura J, Rowin EJ, Chan RH, et al. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc 2024;13:e033565. Go to original source... Go to PubMed...
    20. O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2022;146:e93-e118. Go to original source... Go to PubMed...
    21. Choi SH, Jurgens SJ, Weng LC, et al. Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results from a National Biobank. Circ Res 2020;126:200-209. Go to original source... Go to PubMed...
    22. Bonaventura J, Polakova E, Vejtasova V, Veselka J. Genetic testing in patients with hypertrophic cardiomyopathy. Int J Mol Sci 2021;22:10401. Go to original source... Go to PubMed...
    23. Bonaventura J, Krebsova A, Zoubkova V, et al. Komplexní přístup k pacientům s hypertrofickou kardiomyopatií a indikace ke genetickému vyąetření. Cor Vasa 2020;62:272-278. Go to original source...
    24. Rowin EJ, Orfanos A, Estes NAM, et al. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol 2017;119:1862-1865. Go to original source... Go to PubMed...
    25. Van Velzen HG, Theuns DAMJ, Yap SC, et al. Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2017;119:100-105. Go to original source... Go to PubMed...
    26. Friedman PA, McClelland RL, Bamlet WR, et al. Dual- -chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: The detect supraventricular tachycardia study. Circulation 2006;113:2871-2879. Go to original source... Go to PubMed...
    27. Hindricks G, Potpara T, Kirchhof P, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021;42:373-498. Go to original source... Go to PubMed...
    28. Grünefeld GC, Schulte B, Hohnloser SH, et al. Morphology discrimination: A beat-to-beat algorithm for the discrimination of ventricular from supraventricular tachycardia by implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2001;24:1519-1524. Go to original source... Go to PubMed...
    29. Swerdlow CD, Brown ML, Lurie K, et al. Discrimination of ventricular tachycardia from supraventricular tachycardia by a downloaded wavelet-transform morphology algorithm: A paradigm for development of implantable cardioverter defibrillator detection algorithms. J Cardiovasc Electrophysiol 2002;13:432-441. Go to original source... Go to PubMed...
    30. Lee MA, Corbisiero R, Nabert DR, et al. Clinical results of an advanced SVT detection enhancement algorithm. Pacing Clin Electrophysiol 2005;28:1032-1040. Go to original source... Go to PubMed...
    31. Haresh K, Patel K, Lambiase PD. The subcutaneous ICD - current evidence and challenges. Cardiovasc Diagn Ther 2014;4:449-459.
    32. Gold MR, Theuns DA, Knight BP, et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: The START study. J Cardiovasc Electrophysiol 2012;23:359-366. Go to original source... Go to PubMed...
    33. Zamorano JL, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779. Go to original source... Go to PubMed...
    34. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023;44:3503-3626. Go to original source... Go to PubMed...
    35. Carrick RT, Maron MS, Adler A, et al. Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score. Circ Arrhythm Electrophysiol 2021;14:e009796. Go to original source... Go to PubMed...
    36. Guttmann OP, Pavlou M, O'Mahony C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 2015;17:837-845. Go to original source... Go to PubMed...
    37. Nasser MF, Gandhi S, Siegel RJ, Rader F. Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: A review. Heart Rhythm 2021;18:297-302. Go to original source... Go to PubMed...
    38. Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2023;148:1797-1811. Go to original source... Go to PubMed...
    39. Miller CAS, Maron MS, Estes NAM, et al. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol 2019;123:1859-1862. Go to original source... Go to PubMed...
    40. Chen C, Lal M, Burton Y, et al. Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy. Commun Med 2023;3:99. Go to original source... Go to PubMed...
    41. Castagno D, Di Donna P, Olivotto I, et al. Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes. J Cardiovasc Electrophysiol 2021;32:657-666. Go to original source... Go to PubMed...
    42. Creta A, Elliott P, Earley MJ, et al. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: A European observational multicentre study. Europace 2021;23:1409-1417. Go to original source... Go to PubMed...
    43. Di Donna P, Olivotto I, Delcrè SDL, et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression. Europace 2010;12:347-355. Go to original source... Go to PubMed...
    44. Schaff HV, Juarez-Casso FM. Treatment Strategies for Hypertrophic Cardiomyopathy: Surgical. Am J Cardiol 2024;212:53-63. Go to original source... Go to PubMed...
    45. Robertson JO, Lawrance CP, Maniar HS, Damiano RJ. Surgical techniques used for the treatment of atrial fibrillation. Circ J 2013;77:1941-1951. Go to original source... Go to PubMed...
    46. Boll G, Rowin EJ, Maron BJ, et al. Efficacy of Combined Cox--Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol 2020;125:120-126. Go to original source... Go to PubMed...
    47. Meng Y, Zhang Y, Liu P, et al. Clinical Efficacy and Safety of Cox-Maze IV Procedure for Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy. Front Cardiovasc Med 2021;8:720950. Go to original source... Go to PubMed...
    48. Cui H, Schaff HV, Dearani JA, et al. Does ablation of atrial fibrillation at the time of septal myectomy improve survival of patients with obstructive hypertrophic cardiomyopathy? J Thorac Cardiovasc Surg 2021;161:997-1006. Go to original source... Go to PubMed...
    49. Prystowsky EN. The history of atrial fibrillation: The last 100 years. J Cardiovasc Electrophysiol 2008;19:575-582. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes